NICE is consulting on preliminary draft guidance which covers a suite of five drugs for treating recurrent ovarian cancer.
24 November 2015
In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase alfa (Vimizin, BioMarin Pharma) for the treatment of a very rare inherited lysosomal storage disease when used as part of a managed access agreement.
23 November 2015
The National Institute for Health and Care Excellence (NICE) has published new guidelines to help the NHS reduce the number of babies born before full term.
20 November 2015
NICE – the National Institute for Health and Care Excellence – has issued its first guideline on the use of transfusions in adults, children and young people to ensure they are used only when necessary.
18 November 2015
NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high cholesterol (primary hypercholesterolaemia - heterozygous-familial and non-familial) and mixed dyslipidaemia.
18 November 2015
Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), will not be recommended for routine NHS use because its price remains too high.
17 November 2015
0300 323 0142
(this number rings all our phones and is the best number to contact us on 9:00 – 17:30 Mon - Fri)
(out of office hours number)
Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please contact a member of the team.